Durham pharma nets $238M for smallpox drug with more payouts lined up


The Durham drugmaker could get an additional $124 million in milestone payments from the sale of its smallpox treatment.

Previous Vitamin manufacturer expands in Northeast Philadelphia with 180,000-square-foot lease
Next Hakimian buys riverfront office building for $25 million